An Early Phase 1 interventional study of Exendin-(9-39) and Atropine in Post Bariatric Surgery, Gastric Bypass and Sleeve Gastrectomy, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by The University of Texas Health Science Center at San Antonio · Early Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing avexitide in Hypoglycemia — 3 open to participants now, 4 under way, 1 of them phase 3. avexitide · Hypoglycemia.
Among the 12 studies testing avexitide in Hypoglycemia, this one has the largest planned enrollment, is the only one that started in 2015, is one of 4 in phase 1, and was the 8th registered.
706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.
Browse Hypoglycemia studies →3 of the 12 studies testing avexitide in Hypoglycemia are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 28 across 534 interventional studies indexed under Hypoglycemia.
Median enrollment 18 across the 12 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 7 most frequent:
The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.
The University of Texas Health Science Center at San Antonio has 3 studies filed under Hypoglycemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing avexitide in Hypoglycemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is learn the effect of gastric bypass surgery and sleeve gastrectomy on glucose metabolism mediated by neural and hormonal factors initiated after eating.
The purpose of this study is to determine the weight-independent effects of gastric bypass surgery and sleeve gastrectomy surgery on islet cell response after meal ingestion as mediated by hormonal and neural components of the gut. It will also address the differences between the two procedures.
Such information will be critical for the development of novel approaches for treatment of diabetes as well as improvement of glycemic effects of gastric bypass and sleeve gastrectomy in patients with partial diabetes remission or relapse after complete remission.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For administration of atropine, the following exclusions also apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
Drug: Exendin-(9-39)
to evaluate the effect of neural activation on insulin secretion and glucose metabolism
Drug: Atropine
A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
Also known as: no other name for Exendin-(9-39)
A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
Also known as: Atropine sulfate
Insulin levels measured after nutrient ingestion
Time frame: Each study in the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2015, a primary completion of Aug 2026 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Avexitide · Atropine
The University of Texas Health Science Center at San Antonio →